Abstract
Objectives To use human genetic variants that proxy angiotensin-converting enzyme (ACE) inhibitor drug effects and cardiovascular risk factors to provide insight into how these exposures affect lung ACE2 and TMPRSS2 gene expression and circulating ACE2 levels.
Design Two-sample Mendelian randomization (MR) analysis.
Setting Summary-level genetic association data.
Participants Participants were predominantly of European ancestry. Variants that proxy ACE inhibitor drug effects and cardiometabolic risk factors (body mass index, chronic obstructive pulmonary disease, lifetime smoking index, low-density lipoprotein cholesterol, systolic blood pressure and type 2 diabetes mellitus) were selected from publicly available genome-wide association study data (sample sizes ranging from 188,577 to 898,130 participants). Genetic association estimates for lung expression of ACE2 and TMPRSS2 were obtained from the Gene-Tissue Expression (GTEx) project (515 participants) and the Lung eQTL Consortium (1,038 participants). Genetic association estimates for circulating plasma ACE2 levels were obtained from the INTERVAL study (4,947 participants).
Main outcomes and measures Lung ACE2 and TMPRSS2 expression and plasma ACE2 levels.
Results There were no association of genetically proxied ACE inhibition with any of the outcomes considered here. There was evidence of a positive association of genetic liability to type 2 diabetes mellitus with lung ACE2 gene expression in GTEx (p = 4×10−4) and with circulating plasma ACE2 levels in INTERVAL (p = 0.03), but not with lung ACE2 expression in the Lung eQTL Consortium study (p = 0.68). There were no associations between genetically predicted levels of the other cardiometabolic traits with the outcomes.
Conclusions This study does not provide evidence to support that ACE inhibitor antihypertensive drugs affect lung ACE2 and TMPRSS2 expression or plasma ACE2 levels. In the current COVID-19 pandemic, our findings do not support a change in ACE inhibitor medication use without clinical justification.
What is already known on this topic
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the current coronavirus disease 2019 (COVID-19) pandemic.
Serine protease TMPRSS2 is involved in priming the SARS-CoV-2 spike protein for cellular entry through the angiotensin-converting enzyme 2 (ACE2) receptor.
Expression of ACE2 and TMPRSS2 in the lung epithelium might have implications for risk of SARS-CoV-2 infection and severity of COVID-19.
What this study adds
We used human genetic variants that proxy ACE inhibitor drug effects and cardiometabolic risk factors to provide insight into how these exposures affect lung ACE2 and TMPRSS2 expression and circulating ACE2 levels.
Our findings do not support the hypothesis that ACE inhibitors have effects on ACE2 expression.
We found some support for an association of genetic liability to type 2 diabetes mellitus with higher lung ACE2 expression and plasma ACE2 levels, but evidence was inconsistent across studies.
Competing Interest Statement
All authors have completed the Unified Competing Interest form (available on request from the corresponding author) and declare: DG is a part-time employee of Novo Nordisk. ASB has received grants outside of this work from AstraZeneca, Biogen, BioMarin, Bioverativ, Merck and Novartis and personal fees from Novartis. BEE is on the scientific advisory boards of Freenome and Celsius Therapeutics, and is a full time employee at Genomics plc while on a leave of absence from Princeton University. JEP has received travel and accommodation expenses and hospitality from Olink to speak at Olink-sponsored academic meetings. EP is a full-time employee of Pfizer. JD sits on advisory boards for Novartis, Sanofi, and Astra Zeneca. All other authors have no conflicts of interest to declare.
Funding Statement
DG is supported by the Wellcome 4i Program at Imperial College London (award number 203928/Z/16/Z). SB is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (award number 204623/Z/16/Z). The academic coordinating centre for INTERVAL at Cambridge University was supported by core funding from: NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR BTRU-2014-10024), UK Medical Research Council (MR/L003120/1), British Heart Foundation (SP/09/002; RG/13/13/30194; RG/18/13/33946) and the NIHR (Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust), and Health Data Research UK. SF is funded by the NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR BTRU-2014-10024). JD holds a British Heart Foundation Personal Chair and a National Institute for Health Research Senior Investigator Award. SL is funded by the Swedish Heart-Lung Foundation, the Swedish Research Council, and the Swedish Research Council for Health, Working Life and Welfare. VK is funded by a European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant (721567). VYT is supported by the Cancer Research UK (CRUK) Integrative Cancer Epidemiology Programme (C18281/A19169). SML is supported by an Academic Clinical Fellowship from the NIHR. YB holds a Canada Research Chair in Genomics of Heart and Lung Diseases. JEP is supported by a UKRI Innovation Fellowship at Health Data Research UK (MR/S004068/1). This work was supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and the Wellcome Trust.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Competing interest statement: All authors have completed the Unified Competing Interest form (available on request from the corresponding author) and declare: DG is a part-time employee of Novo Nordisk. ASB has received grants outside of this work from AstraZeneca, Biogen, BioMarin, Bioverativ, Merck and Novartis and personal fees from Novartis. BEE is on the scientific advisory boards of Freenome and Celsius Therapeutics, and is a full time employee at Genomics plc while on a leave of absence from Princeton University. JEP has received travel and accommodation expenses and hospitality from Olink to speak at Olink-sponsored academic meetings. EP is a full-time employee of Pfizer. JD sits on advisory boards for Novartis, Sanofi, and Astra Zeneca. All other authors have no conflicts of interest to declare.
Transparency declaration: The corresponding authors affirm that the manuscript is an honest, accurate, and transparent account of the research being reported, and that no important aspects of the study have been omitted.
Dissemination declaration: This work uses genetic association summary data from published studies and dissemination to the participants that contributed these data is therefore not possible.
Copyright: The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in BMJ editions and any other BMJPGL products and sublicences such use and exploit all subsidiary rights, as set out in our licence.
Funding: DG is supported by the Wellcome 4i Program at Imperial College London (award number 203928/Z/16/Z). SB is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (award number 204623/Z/16/Z). The academic coordinating centre for INTERVAL at Cambridge University was supported by core funding from: NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR BTRU-2014-10024), UK Medical Research Council (MR/L003120/1), British Heart Foundation (SP/09/002; RG/13/13/30194; RG/18/13/33946) and the NIHR (Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust), and Health Data Research UK. SF is funded by the NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR BTRU-2014-10024). JD holds a British Heart Foundation Personal Chair and a National Institute for Health Research Senior Investigator Award. SL is funded by the Swedish Heart-Lung Foundation, the Swedish Research Council, and the Swedish Research Council for Health, Working Life and Welfare. VK is funded by a European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant (721567). VYT is supported by the Cancer Research UK (CRUK) Integrative Cancer Epidemiology Programme (C18281/A19169). SML is supported by an Academic Clinical Fellowship from the NIHR. YB holds a Canada Research Chair in Genomics of Heart and Lung Diseases. JEP is supported by a UKRI Innovation Fellowship at Health Data Research UK (MR/S004068/1). This work was supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and the Wellcome Trust.
Data Availability
The data used in this work are obtained from published studies that obtained relevant participant consent and ethical approval. All variants used as instruments and their genetic association estimates were selected from publicly available data sources, and are provided in Supplementary Tables 1-8. GWAS summary data for all the outcomes considered in this study are publicly available at http://dx.doi.org/10.6084/m9.figshare.12102681 (GTEx), http://dx.doi.org/10.6084/m9.figshare.12102711 (Lung eQTL Consortium), and http://dx.doi.org/10.6084/m9.figshare.12102777 (INTERVAL).
http://dx.doi.org/10.6084/m9.figshare.12102681
